Diffuse leptomeningeal glioneuronal tumour
Diffuse leptomeningeal glioneuronal tumour (also previously known as disseminated oligodendroglial-like leptomeningeal tumour of childhood) is a rare and only recently described tumour of the central nervous system included in the WHO classification of CNS tumours in the 2016 update 2,5. Morphologically it appears as prominent leptomeningeal enhancement, often without a readily identifiable parenchymal component and leads to difficult to treat hydrocephalus.
These tumours are most commonly encountered in children and adolescents, with the vast majority of reported cases in individuals less than 18 years of age 2,5. Occasionally they are encountered in young to middle-aged adults 5. There appears to be a moderate male predilection 5.
Clinical presentation is dominated by hydrocephalus due to pronounced accumulation of tumour within the subarachnoid space. Occasionally patient may present with focal neurological symptoms, including cranial nerve impairment, ataxia and spinal cord compression, or with seizures 3,5.
These tumours histologically are composed intense desmoplastic fibrous response admixed with cells with perinuclear haloes and cytoplasmic swelling similar to oligodendroglial cells. They have round to oval nuclei with finely granular dispersed chromatin and inconspicuous nucleoli 1,5.
This morphology, combined with common chromosome arm 1p deletions, sometimes with co-deletion of 19q, accounts for it prior name including the term "oligodendroglial-like" (see 1p19q codeletion). In contrast to oligodendrogliomas, diffuse leptomeningeal glioneuronal tumours do not have IDH mutations 2,5.
Other markers identified include 2,3,5:
- KIAA1549-BRAF fusion (common)
- OLIG2 (patchy immunoreactivity)
- MAP2 (diffuse immunoreactivity)
- S-100 (diffuse immunoreactivity)
- GFAP (patchy immunoreactivity) seen in less than 50% of cases
- synaptophysin (diffuse immunoreactivity) seen in over two thirds of cases
Negative for neurofilament and EMA, and no IDH mutations 1,2,5.
The vast majority of reported cases are low-grade, indolent tumours and have a commensurately low mitotic index (<1%) 1. A few cases with cellular anaplasia and increased mitotic rate and even microvascular proliferation have been reported, and these have, not surprisingly, had more aggressive clinical course 3,5.
Imaging is ideally carried out with MRI although CT will demonstrate many of the same features, within its limitations.
The dominant finding is of thick nodular leptomeningeal enhancement particularly around the basal cisterns and extending over the surface of the brain and spinal cord 1.
A further finding, which is believed to be fairly specific for this entity, is the presence of numerous small subpial cysts (high T2, low T1, FLAIR attenuating) located over the surface of the inferior parts of the cerebral hemispheres (temporal lobes, inferior frontal lobes), posterior fossa (cerebellum and brainstem) and spinal cord 5. It is thought that perhaps these represent dilatation of the perivascular spaces (Virchow-Robin spaces) 1.
Importantly there is often no definitely dominant primary parenchymal mass identified 1. In many patients, however, discrete intraparenchymal lesions can be identified, most frequently in the spinal cord 5.
Treatment and prognosis
Although diffuse leptomeningeal glioneuronal tumours demonstrate fairly indolent growth, morbidity is fairly prominent due to profound hydrocephalus 2. Complicating matters is that the entity is only newly described and the literature is confusing; it is unclear if all reported cases are in fact of the one entity. Survival varies widely, in some instances reported to be quite low, with an average survival of only 22 months 3, whereas in other series have long follow-up 4.
The differential is essentially that of leptomeningeal enhancement, with the florid nature of enhancement particularly reminiscent of tuberculous leptomeningitis. Other causes to particularly consider include:
- 1. Gardiman MP, Fassan M, Orvieto E et-al. Diffuse leptomeningeal glioneuronal tumors: a new entity?. Brain Pathol. 2010;20 (2): 361-6. doi:10.1111/j.1750-3639.2009.00285.x - Pubmed citation
- 2. Louis DN, Perry A, Reifenberger G et-al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131 (6): 803-20. doi:10.1007/s00401-016-1545-1 - Pubmed citation
- 3. Cho HJ, Myung JK, Kim H et-al. Primary diffuse leptomeningeal glioneuronal tumors. Brain Tumor Pathol. 2015;32 (1): 49-55. doi:10.1007/s10014-014-0187-z - Pubmed citation
- 4. Preuss M, Christiansen H, Merkenschlager A et-al. corrected. J. Neurooncol. 2015;124 (1): 65-74. doi:10.1007/s11060-015-1735-z - Pubmed citation
- 5. David N. Louis, Hiroko Ohgaki, Otmar D. Wiestler and Wbster K. Cavenee. International Agency for Research on Cancer, WHO Classification of Tumours of the Central Nervous System. 2016 Revision ISBN: 9789283244929